Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release ofTrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterizediPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research.
https://mma.prnewswire.com/media/2503349/Trailhead_Main_Logo.jpg
TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid anderythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling.
Designed for applications such ashematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results.
“TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models,” said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. “Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development.”
“TheseHematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility,” said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. “Their robust marker expression andmultilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates.”
Cell characterization information and additional data can be found atTrailBio.com.
AboutTrailhead Biosystems
Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allowsTrailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio®Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation.
Learn more aboutTrailhead Biosystems, TrailBio®Hematopoietic Progenitor Cells and HD-DoE® atwww.TrailBio.com.
For more information, please contact:
TimMauk, Corporate CommunicationsTrailhead BiosystemsEmail:info@trailbio.com
https://c212.net/c/img/favicon.png?sn=CL43917&sd=2025-08-05
View original content to download multimedia:https://www.prnewswire.com/news-releases/trailhead-biosystems-expands-ipsc-derived-portfolio-with-trailbio-hematopoietic-progenitor-cells-302521167.html
SOURCE Trailhead Biosystems Inc
https://rt.newswire.ca/rt.gif?NewsItemId=CL43917&Transmission_Id=202508050500PR_NEWS_USPR_____CL43917&DateId=20250805